NasdaqGS:STOKBiotechs
A Look At Stoke Therapeutics (STOK) Valuation After NEJM Zorevunersen Dravet Syndrome Data Publication
Stoke Therapeutics (STOK) shares are back in focus after the company and Biogen published clinical data for zorevunersen in The New England Journal of Medicine, highlighting multiyear seizure and cognitive outcomes in Dravet syndrome.
See our latest analysis for Stoke Therapeutics.
The latest New England Journal of Medicine data come after a strong run for Stoke, with a 1 year total shareholder return of over 7x, a 30 day share price return of 9.51%, and a year to date share price return of...